Indeed, our recent preclinical study has demonstrated that a Toll-like receptor-3 ligand poly-ICLC, which has been extensively evaluated for safety in patients with glioma [37], enhances type-1 anti-glioma immunity when combined with peripheral vaccine regimens [38]. The gene discussed is TLR3; the disease is glioma.